Extended Data Fig. 2: Clearance of rATG and Fludarabine in Context of Conditioning Regimen Containing Briquilimab. | Nature Medicine

Extended Data Fig. 2: Clearance of rATG and Fludarabine in Context of Conditioning Regimen Containing Briquilimab.

From: Irradiation- and busulfan-free stem cell transplantation in Fanconi anemia using an anti-CD117 antibody: a phase 1b trial

Extended Data Fig. 2

Given the graft rejection that was observed in prior dose de-escalation of TBI from FA allo-HSCT protocols, close pharmacokinetic monitoring of rATG and fludarabine was performed to ensure concurrent optimal immunosuppression was administered. a) rATG: Patient 1 received 2.5 mg/kg IV for 3 doses starting on day −9. The pre-HSCT AUC was estimated to be below goal at 14.6 AU*day/mL, while post-HSCT AUC was estimated to be within goal at 2.31 AU*day/mL. Given the low pre-HSCT AUC for Patient 1, the rATG dose was increased for Patients 2 and 3 to 4 mg/kg IV for 3 doses starting on day −10. b) Fludarabine: Cumulative AUC (cAUC) for Patient 1 was within the previously published goal and the same dosing of 35 mg/m2 IV for 4 doses was maintained for Patients 2 and 3.

Back to article page